Education
About Us
Working with TipRanks
Follow Us
MAIA Biotechnology, Inc. (MAIA)
:MAIA
RESEARCH TOOLSreports
MAIA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.41 - $5.99
Previous CloseN/A
Volume259.27K
Average Volume (3M)145.69K
Market Cap
$44.38M
Enterprise Value$58.45M
Total Cash (Recent Filing)$663.46K
Total Debt (Recent Filing)$463.75K
Price to Earnings (P/E)―
Beta0.95
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.11
Shares Outstanding29,587,315
10 Day Avg. Volume89,212
30 Day Avg. Volume145,692
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-3.20
P/FCF Ratio0.00
Enterprise Value/Market Cap1.32
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-2.67
Forecast
1Y Price Target
$14.00Price Target Upside833.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
MAIA Biotechnology, Inc. News
PremiumCompany Announcements
MAIA Biotechnology Showcases THIO-101 Trial at ELCC 2025
---
Ownership Overview
17.22% Insiders
3.01% Mutual Funds
1.36% Other Institutional Investors
76.10% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
MAIA FAQ
What was MAIA Biotechnology, Inc.’s price range in the past 12 months?
MAIA Biotechnology, Inc. lowest stock price was $1.41 and its highest was $5.99 in the past 12 months.
What is MAIA Biotechnology, Inc.’s market cap?
MAIA Biotechnology, Inc.’s market cap is $44.38M.
When is MAIA Biotechnology, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were MAIA Biotechnology, Inc.’s earnings last quarter?
MAIA Biotechnology, Inc. released its earnings results on Aug 19, 2024. The company reported -$0.5 earnings per share for the quarter, missing the consensus estimate of -$0.415 by -$0.085.
Is MAIA Biotechnology, Inc. overvalued?
According to Wall Street analysts MAIA Biotechnology, Inc.’s price is currently Undervalued.
Does MAIA Biotechnology, Inc. pay dividends?
MAIA Biotechnology, Inc. does not currently pay dividends.
What is MAIA Biotechnology, Inc.’s EPS estimate?
MAIA Biotechnology, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does MAIA Biotechnology, Inc. have?
MAIA Biotechnology, Inc. has 29,587,315 shares outstanding.
What happened to MAIA Biotechnology, Inc.’s price movement after its last earnings report?
MAIA Biotechnology, Inc. reported an EPS of -$0.5 in its last earnings report, missing expectations of -$0.415. Following the earnings report the stock price went up 3.922%.
Which hedge fund is a major shareholder of MAIA Biotechnology, Inc.?
Currently, no hedge funds are holding shares in MAIA
---
MAIA Biotechnology, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$14.00 (833.33% Upside)
$14.00 (833.33% Upside)
Blogger Sentiment
Bullish
MAIA Sentiment 100%
Sector Average 68%
Sector Average 68%
Crowd Wisdom
Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 0.4%
Last 30 Days ▼ 0.4%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-31.81%
12-Months-Change
Fundamentals
Return on Equity
-1131.02%
Trailing 12-Months
Asset Growth
34.21%
Trailing 12-Months
Company Description
MAIA Biotechnology, Inc.
MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer, primarily non-small cell lung cancer. Its lead asset, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company was founded in 2018 and is headquartered in Chicago, Illinois.
---
MAIA Stock 12 Month Forecast
Average Price Target
$14.00
▲(833.33% Upside)
Technical Analysis
Bioline RX Ltd Sponsored ADR
―
Affimed
―
Cellectar Biosciences
―
Cyclerion Therapeutics
―
Galera Therapeutics
―
Best Analysts Covering MAIA
1 Year
1 Year Success Rate
5/13 ratings generated profit
1 Year Average Return
-11.71%
reiterated a buy rating last month
Copying Robert LeBoyer's trades and holding each position for 1 Year would result in 38.46% of your transactions generating a profit, with an average return of -11.71% per trade.
---